Sarepta Therapeutics, Inc..
SRPT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The company's portfolio includes multiple approved products for Duchenne muscular dystrophy (DMD), a rare genetic d...Show More
Better Health for All
0
No evidence available to assess Sarepta Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess Sarepta Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
50
In 2023, Sarepta's CEO-to-median employee pay ratio was 5:1.
1
The company's Total Recordable Incident Rate (TRIR) was 0.23 in 2023, which is significantly below the 2022 industry average of 0.9.
2
A bi-annual pay equity analysis conducted in 2023 found no statistical evidence of gender or racial pay disparities.
3
The voluntary employee turnover rate for 2023 was 3.39%.
4
The company reported zero fines or violations related to labor laws in the past two years. Sarepta offers a comprehensive total rewards package that includes healthcare benefits, paid time off, family leave, and an Employee Assistance Program, indicating 100% health insurance coverage for employees.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Sarepta Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
No specific, concrete evidence was found in the provided articles to assess Sarepta Therapeutics, Inc. against any of the defined KPIs for the 'Honest & Fair Business' value. While articles mentioned the existence of a formal whistleblower protection policy, they lacked the specific details required by the rubric to determine its strength or enforcement, such as hotline statistics, reporting mechanisms, or training frequency.
1
Therefore, all KPIs are omitted due to insufficient data.
Kind to Animals
-60
Sarepta Therapeutics conducts animal testing for developing and commercializing medical products, including pre-clinical trials and efficacy studies for drugs like AVI-7288.
1
There is no explicit animal testing policy mentioned that outlines reduction, restriction, or prohibition of testing, nor any details on oversight or alternative methods.
2
The company's sustainability report does not provide data on the volume of animals used in testing.
3
The absence of transparent reduction targets, coupled with confirmed animal testing, indicates a lack of commitment to minimizing animal use.
No War, No Weapons
0
No evidence available to assess Sarepta Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
-40
Sarepta Therapeutics reported Scope 1 and 2 GHG emissions of 7,590 tCO2e in 2023, a decrease from 8,328 tCO2e in 2022.
1
Scope 3 emissions are not reported.
2
The company is not participating in tracked SBTi initiatives.
3
Its waste diversion rate was 31% in 2023, an increase from 19% in 2022.
4
Sarepta has a net-zero target year of 2025 for near-zero Scope 1 & 2 emissions and a 2030 target for a 30% reduction from a 2022 baseline for Scope 1 & 2 emissions.
5
Respect for Cultures & Communities
0
The company has a third-party mechanism for employees and others to anonymously report violations of the Code of Conduct.
1
This is considered a standard grievance process, but the evidence does not specify it as a community-specific mechanism or detail its coverage across operational sites.
Safe & Smart Tech
-20
Sarepta Therapeutics has not experienced any material cybersecurity incidents as of February 2026, indicating no breaches in the past three years.
1
The company adheres to the EU-U.S. Data Privacy Framework, its UK Extension, and the Swiss-U.S. Data Privacy Framework.
2
Sarepta provides users with rights to access, rectify, erase, and restrict processing of their personal data, and to withdraw consent, by contacting their Data Protection Officer.
3
The company maintains a Comprehensive Compliance Program, is in material compliance with California Health & Safety Code section 119402, and adheres to OIG and PhRMA guidelines.
4
Sarepta conducts annual penetration tests and monthly vulnerability scans, with results reported to senior management and the Audit Committee.
5
The company has a cybersecurity incident response plan and a formal vulnerability disclosure program.
6
Privacy considerations are integrated into product development, with efforts to provide choices regarding data collection and use.
7
Security testing includes annual penetration tests and monthly vulnerability scans.
8
Sarepta collects anonymized medical and health-related information and aims to anonymize or remove unnecessary identifiers from records beyond specified retention periods.
9
Employee cybersecurity awareness training is provided.
10
The company stores information on secure servers behind firewalls.
11
Zero Waste & Sustainable Products
0
No evidence available to assess Sarepta Therapeutics, Inc. on Zero Waste & Sustainable Products.